[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JPS6479125A - Antitumor agent - Google Patents

Antitumor agent

Info

Publication number
JPS6479125A
JPS6479125A JP62201509A JP20150987A JPS6479125A JP S6479125 A JPS6479125 A JP S6479125A JP 62201509 A JP62201509 A JP 62201509A JP 20150987 A JP20150987 A JP 20150987A JP S6479125 A JPS6479125 A JP S6479125A
Authority
JP
Japan
Prior art keywords
alpha
active substance
ifn
units
antitumor agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP62201509A
Other languages
Japanese (ja)
Inventor
Koichiro Otsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to JP62201509A priority Critical patent/JPS6479125A/en
Publication of JPS6479125A publication Critical patent/JPS6479125A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PURPOSE:To obtain an antitumor agent showing excellently antitumor effects, having administration form for intramuscular injection, containing IL-2 active substance and IFN-alpha active substance. CONSTITUTION:An antitumor agent which comprises interleukin-2 (IL-2) active substance and interferon-alpha (IFN-alpha) active substance in the ratio of 1mcg protein mass (35 units as IL-2 activity) of IL-2 and 5X10<5>-5X10<8> units, preferably 5X10<5>-10<8> units IFN-alpha and has an administration form for intramuscular injection. Further combination of muramyl dipeptide shown by the formula (R<1> is OH or carboxylic acid residue; R<2> and R<3> are H or 1-6C alkyl which may be replaced with OH; R<4> is OH or 1-6C alkoxy; R<5> is OH or amino replaced) shows strongly antitumor action with a smaller amount.
JP62201509A 1986-08-13 1987-08-11 Antitumor agent Pending JPS6479125A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP62201509A JPS6479125A (en) 1986-08-13 1987-08-11 Antitumor agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP19082986 1986-08-13
JP62201509A JPS6479125A (en) 1986-08-13 1987-08-11 Antitumor agent

Publications (1)

Publication Number Publication Date
JPS6479125A true JPS6479125A (en) 1989-03-24

Family

ID=26506338

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62201509A Pending JPS6479125A (en) 1986-08-13 1987-08-11 Antitumor agent

Country Status (1)

Country Link
JP (1) JPS6479125A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005523878A (en) * 2001-09-28 2005-08-11 パーデュー・リサーチ・ファウンデーション Treatment method using ligand / immunogen complex
US8105608B2 (en) 2000-03-31 2012-01-31 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
US8168164B2 (en) 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004030113A (en) * 2002-06-25 2004-01-29 Yamatake Corp Informing device
JP2006254077A (en) * 2005-03-10 2006-09-21 Sharp Corp Network setting device
JP2007013491A (en) * 2005-06-29 2007-01-18 Toshiba Corp Radio apparatus, radio system, and radio communication method
WO2012004939A1 (en) * 2010-07-07 2012-01-12 パナソニック株式会社 Communication device and communication method
WO2013121758A1 (en) * 2012-02-15 2013-08-22 パナソニック株式会社 Terminal device, communication method therefor, and communication module
JP2014137782A (en) * 2013-01-18 2014-07-28 Nec Access Technica Ltd Communication device and method for shifting operation states of communication device
JP2015029262A (en) * 2013-06-28 2015-02-12 キヤノン株式会社 Communication system, communication terminal, information processing device, control method and program
JP2015076838A (en) * 2013-10-11 2015-04-20 横河電機株式会社 Radio module and radio device

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004030113A (en) * 2002-06-25 2004-01-29 Yamatake Corp Informing device
JP2006254077A (en) * 2005-03-10 2006-09-21 Sharp Corp Network setting device
JP2007013491A (en) * 2005-06-29 2007-01-18 Toshiba Corp Radio apparatus, radio system, and radio communication method
WO2012004939A1 (en) * 2010-07-07 2012-01-12 パナソニック株式会社 Communication device and communication method
WO2013121758A1 (en) * 2012-02-15 2013-08-22 パナソニック株式会社 Terminal device, communication method therefor, and communication module
JP2014137782A (en) * 2013-01-18 2014-07-28 Nec Access Technica Ltd Communication device and method for shifting operation states of communication device
JP2015029262A (en) * 2013-06-28 2015-02-12 キヤノン株式会社 Communication system, communication terminal, information processing device, control method and program
JP2015076838A (en) * 2013-10-11 2015-04-20 横河電機株式会社 Radio module and radio device

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8105608B2 (en) 2000-03-31 2012-01-31 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
JP2005523878A (en) * 2001-09-28 2005-08-11 パーデュー・リサーチ・ファウンデーション Treatment method using ligand / immunogen complex
US8168164B2 (en) 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation

Similar Documents

Publication Publication Date Title
AU590618B2 (en) Stable formulation of biologically active proteins for parenteral injection
MY128629A (en) Stabilized interleukin 2
KR900018098A (en) Pyridone Carboxylic Acids and Antibacterials
IL85523A (en) Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it
ZA907338B (en) Thienylcarboxylates of amino alcohols
BG109523A (en) Kit for parenteral administration of stable interferon formulations
WO1987003480A3 (en) Medicament with anti-tumoral action containing hexadecylphosphocholine
ES2090132T3 (en) INTERLEUKIN-3 (IL-3) VARIANTS WITH ADDED CYSTEINE AND ITS CHEMICAL MODIFICATIONS.
NZ508301A (en) Polyethylene glycol-polyorthoester, polyethylene glycol-polyorthoester-polyethylene glycol, and polyorthoester-polyethylene glycol-polyorthoester block copolymers
PL316942A1 (en) Novel pharmaceutic compositions based on taxoides
MY101784A (en) Novel pharmacological compounds
ATE138099T1 (en) NON-GLYCOSATED PROTEINS, ANALOGUES OF HUMAN INTERLEUKIN-3
KR910020032A (en) Derivatized protein or polypeptide and pharmaceutical composition comprising the same
MX9703642A (en) Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein.
CA2056421A1 (en) Agent against autoimmune diseases
ATE184798T1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING HGH
DK0641216T3 (en) Pharmaceutical preparation containing IL-6
JPS6479125A (en) Antitumor agent
ES460620A1 (en) Psychopharmacologically active peptides and peptide-derivatives, and the use thereof
GB8713849D0 (en) Acaricidal formulation
IE871358L (en) Interferon for carcinoma
KR880002542A (en) Antitumor agents
EP0335446A3 (en) Agents for treating neoplasms
KR920700683A (en) solubilization of t-PA
ZA885227B (en) Injection containing 3-benzoyloxy-1,3,5(10)-estratriene-17-(4-(p-(bis(2-chloroethyl)amino)phenyl)-butanoyloxy)acetate as an active ingredient